Asset Details
Do you wish to reserve the book?
A 96-Week Comparison of Lopinavir-Ritonavir Combination Therapy Followed by Lopinavir-Ritonavir Monotherapy versus Efavirenz Combination Therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A 96-Week Comparison of Lopinavir-Ritonavir Combination Therapy Followed by Lopinavir-Ritonavir Monotherapy versus Efavirenz Combination Therapy
Do you wish to request the book?
A 96-Week Comparison of Lopinavir-Ritonavir Combination Therapy Followed by Lopinavir-Ritonavir Monotherapy versus Efavirenz Combination Therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A 96-Week Comparison of Lopinavir-Ritonavir Combination Therapy Followed by Lopinavir-Ritonavir Monotherapy versus Efavirenz Combination Therapy
2008
Overview
Antiretroviral-naive HIV-1-infected volunteers received zidovudine/lamivudine plus either lopinavir/ritonavir (n = 104) or efavirenz (n = 51). Lopinavir/ritonavir-treated subjects demonstrating 3 consecutive monthly HIV-1 RNA levels <50 copies/mL started lopinavir/ritonavir monotherapy. In previous-failure=failure analysis, 48% (lopinavir/ritonavir) and 61% (efavirenz) maintained HIV-1 RNA at <50 copies/mL through week 96, (P = .17; 95% confidence interval [CI] for the difference, −29% to 4%); in noncompletion=failure analysis, 60% (lopinavir/ritonavir) and 63% (efavirenz) maintained HIV-1 RNA at <50 copies/mL at week 96 (P = .73; 95% CI for the difference, −19% to 13%). Significant sparing of peripheral lipoatrophy was noted in the lopinavir/ritonavir simplification strategy. This study has provided important information for future studies using treatment simplified to lopinavir/ritonavir monotherapy. Trial registration. ClinicalTrials.gov identifier: NCT00075231.
Publisher
The University of Chicago Press,University of Chicago Press
Subject
Acquired Immunodeficiency Syndrome - blood
/ Acquired Immunodeficiency Syndrome - drug therapy
/ AIDS
/ Anti-HIV Agents - adverse effects
/ Anti-HIV Agents - therapeutic use
/ Benzoxazines - therapeutic use
/ Biological and medical sciences
/ Diarrhea - chemically induced
/ Fundamental and applied biological sciences. Psychology
/ HIV 1
/ HIV Protease Inhibitors - adverse effects
/ HIV Protease Inhibitors - therapeutic use
/ HIV/AIDS
/ Human immunodeficiency virus 1
/ Humans
/ Pyrimidinones - therapeutic use
/ RNA
/ Virology
